For the Inventor, By the Inventor

Enter assignee name

Watertown, MA, United States of America

Forma Therapeutics, Inc.

USPTO Granted Patents = 125

CIPO Patents = 3

EPO Patents = 27

Trademarks = 4

Forward Citations = 1,185

Loading Chart...

Loading Chart...

88 inventors (with patents filed for the assignee):

David R Lancia, Jr (76 out of 113 patents)

Matthew W Martin (50 out of 74 patents)

Xiaozhang Zheng (43 out of 107 patents)

4. David S Millan (38 out of 47 patents)

5. Bingsong Han (35 out of 75 patents)

6. Pui Yee Ng (35 out of 79 patents)

7. Aleksandra Rudnitskaya (34 out of 53 patents)

8. Kenneth W Bair (33 out of 82 patents)

9. Cuixian Liu (31 out of 55 patents)

10. Ann-Marie Campbell (31 out of 59 patents)

11. Jennifer R Thomason (30 out of 46 patents)

12. Mary-Margaret Zablocki (30 out of 48 patents)

13. Wei Lu (29 out of 39 patents)

14. Anna M Ericsson (29 out of 58 patents)

15. Gary Gustafson (28 out of 44 patents)

Core Competencies:

Cyclic AMP-Responsive Element-Binding Protein

Mutant Isocitrate Dehydrogenase

Ubiquitin-Specific Protease Inhibitors

Pyruvate Kinase Activators

Bromodomain Inhibitors

Fatty Acid Synthase Inhibitors

Quinolinone Derivatives

Tetrahydroquinoline Compositions

Fused Bicyclic Compounds

Pyrrolopyrrole Compositions

Purinones

HDAC Inhibitors

125 patents: Sort by Forward Citations

1. 12454532 - Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP) (2025-10-28),

2. 12378242 - Inhibiting CREB binding protein (CBP) (2025-08-05),

3. 12351577 - Inhibiting cyclic AMP-responsive element-binding protein (CREB) (2025-07-08),

4. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2025-04-14),

5. 12053463 - Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile (2024-08-06),

6. 12049466 - Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors (2024-07-30),

7. 12043623 - Purinones as ubiquitin-specific protease 1 inhibitors (2024-07-23),

8. 11963956 - Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) (2024-04-23),

9. 11814386 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors (2023-11-14),

10. 11801243 - Bromodomain inhibitors for androgen receptor-driven cancers (2023-10-31),

11. 11795168 - Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) (2023-10-24),

12. 11787803 - Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors (2023-10-17),

13. 11738018 - Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) (2023-08-29),

14. 11723905 - Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile (2023-08-15),

15. 11649242 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators (2023-05-16),

FORMA Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of transformative medicines. With a strong emphasis on innovative science, FORMA combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates targeting historically difficult-to-drug targets. The company's programs span multiple therapeutic areas including oncology, hematology, and rare diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

125 Patents

#3 in Watertown, MA

#166 in Massachusetts

#2,982 in US

#6,230 in the World

Watertown, MA, United States of America

Forma Therapeutics, Inc.

Forward Citations = 1,185

88 inventors:

David R Lancia, Jr (76 out of 113 patents)

Matthew W Martin (50 out of 74 patents)

Xiaozhang Zheng (43 out of 107 patents)

4. David S Millan (38 out of 47 patents)

5. Bingsong Han (35 out of 75 patents)

Please report any incorrect information to support@idiyas.com

Loading…